美多芭联合盐酸普拉克索治疗帕金森病的临床研究

Abstract
Figure/Table
References (15)
Related Citation (5)

Download: PDF (0 KB) HTML (35 KB)
Export: BibTeX | EndNote (RIS)

Abstract ObjectiveTo investigate the therapeutic effect Madopar combined with Pramipexole Hydrochloride for the treatment of Parkinson′s disease.MethodsAltogether 124 patients with Parkinson′s disease who were treated in our hospital from April 2013 to April 2016 were selected as the research objects and divided into control group(62 cases,treated with Madopar)and observation group (62 cases,treated with Madopar combined with Pramipexole Hydrochloride)according to the random number method.The treatment efficiency,Parkinson′s score scale (UP-DRS),quality of life scale(ADL)score and clinical adverse reactions were compared between the two groups.ResultsBefore the treatment,the UP-DRS score of patients in two groups were compared,and the difference was not statistically significant(P＞0.05).While in 6 weeks and 12 weeks after treatment,the observation group of patients with the UP-DRS scores were significantly lower than the control group,the differences were statistically significant(P＜0.05).The total incidence of adverse reactions in the two groups was compared,and the difference was not statistically significant(P＞0.05).The ADL score of the patients in the observation group was significantly higher than that in the control group,and the difference was statistically significant(P＜0.05).The total effective rate of treatment in the observation group was significantly higher than that in the control group,and the difference was statistically significant(P＜0.05).ConclusionThe therapeutic effect of Madopar combined with Pramipexole Hydrochloride for the treatment of Parkinson′s disease is significantly improved,and it is worth promoting to improve treatment efficiency without increasing the adverse reaction of patients.

Key words： Parkinson&prime s disease Madopar Pramipexole Hydrochloride Therapeutic effect

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YANG Xing-hong
	SU Yu-rong
	LI Xin

Cite this article:

YANG Xing-hong,SU Yu-rong,LI Xin. Clinical study of Madopar combined with Pramipexole Hydrochloride for the treatment of Parkinson′s disease[J]. 中国当代医药, 2017, 24(35): 125-127.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2017/V24/I35/125

[1]	彭文君.盐酸普拉克索联合美多芭治疗帕金森病的临床疗效[J].中国现代医生，2012，50（5）:58-59.
[2]	刘志强，朴钟源，刘永丹，等.美多芭联合盐酸普拉克索治疗帕金森病对运动功能的作用[J].中国实用神经疾病杂志，2015，18（15）:94-95.
[3]	刘海波.中西医结合治疗帕金森病90例临床疗效观察[J].中医临床研究，2015，7（23）:5-7.
[4]	陈斌.盐酸普拉克索联合美多芭治疗帕金森病56例临床观察[J].河北联合大学学报，2014，16（2）:224-225.
[5]	黄载文.美多芭联合盐酸普拉克索对帕金森病患者运动功能的影响[J].中国实用神经疾病杂志，2013，16（11）:74-75.[6]柏雪，胡凤云.青年型帕金森病诊断与治疗[J].中国实用医刊，2013，40（21）:89-90.
[7]	郭进春，王璋，常斌宾，等.高龄帕金森病因急性肠损伤继发恶性撤药综合征1例[J].中华保健医学杂志，2016，18（3）:251-252.
[8]	罗丽霞.盐酸普拉克索联合美多芭治疗100例帕金森病的临床研究[J].海峡药学，2016，28（9）:86-87.
[9]	刘越存，黎展鸿，陈雄辉.美多芭联合盐酸普拉克索治疗对帕金森病患者焦虑抑郁状态及血清炎症因子水平的影响[J].中国医药科学，2017，7（7）:12-15.
[10]	郑江环.预防性给予小剂量艾司西酞普兰对帕金森患者抑郁及整体症状疗效分析[J].重庆医学，2014，48（21）:2725-2727.
[11]	梁玉山，蓝壁幸.美多芭联合脑得生治疗帕金森综合征疗效观察[J].中国药物经济学，2013，8（1）:80-81.
[12]	梁容仙，廖仁昊.卡左双多巴控释片联合吡贝地尔治疗晚期帕金森病的临床观察[J].中国药物与临床，2013，13（5）:638-639.
[13]	裴文慧，刘继馨，吴嘉瑞.基于中医传承辅助系统的治疗帕金森病方剂组方规律分析[J].中国实验方剂学杂志，2014，20（3）:205-208.
[14]	刘桂香.中西医结合治疗帕金森抑郁的疗效及其安全性评价[J].中医药导报，2013，19（9）:37-39.
[15]	胡智伟，王浩，邹小东，等.帕金森叠加综合征相关疾病的临床诊断[J].神经疾病与精神卫生，2012，12（5）:503-505.